Literature DB >> 25705847

Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation.

Martin Lauss1, Rizwan Haq2, Helena Cirenajwis1, Bengt Phung3, Katja Harbst1, Johan Staaf1, Frida Rosengren3, Karolina Holm1, Mattias Aine3, Karin Jirström4, Åke Borg1, Christian Busch5, Jürgen Geisler6, Per E Lønning5, Markus Ringnér1, Jillian Howlin3, David E Fisher2, Göran Jönsson7.   

Abstract

The microphthalmia-associated transcription factor (MITF) is a key regulator of melanocyte development and a lineage-specific oncogene in melanoma; a highly lethal cancer known for its unpredictable clinical course. MITF is regulated by multiple intracellular signaling pathways, although the exact mechanisms that determine MITF expression and activity remain incompletely understood. In this study, we obtained genome-wide DNA methylation profiles from 50 stage IV melanomas, normal melanocytes, keratinocytes, and dermal fibroblasts and utilized The Cancer Genome Atlas data for experimental validation. By integrating DNA methylation and gene expression data, we found that hypermethylation of MITF and its co-regulated differentiation pathway genes corresponded to decreased gene expression levels. In cell lines with a hypermethylated MITF-pathway, overexpression of MITF did not alter the expression level or methylation status of the MITF pathway genes. In contrast, however, demethylation treatment of these cell lines induced MITF-pathway activity, confirming that gene regulation was controlled via methylation. The discovery that the activity of the master regulator of pigmentation, MITF, and its downstream targets may be regulated by hypermethylation has significant implications for understanding the development and evolvement of melanoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25705847      PMCID: PMC4720161          DOI: 10.1038/jid.2015.61

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  42 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

Authors:  Houtan Noushmehr; Daniel J Weisenberger; Kristin Diefes; Heidi S Phillips; Kanan Pujara; Benjamin P Berman; Fei Pan; Christopher E Pelloski; Erik P Sulman; Krishna P Bhat; Roel G W Verhaak; Katherine A Hoadley; D Neil Hayes; Charles M Perou; Heather K Schmidt; Li Ding; Richard K Wilson; David Van Den Berg; Hui Shen; Henrik Bengtsson; Pierre Neuvial; Leslie M Cope; Jonathan Buckley; James G Herman; Stephen B Baylin; Peter W Laird; Kenneth Aldape
Journal:  Cancer Cell       Date:  2010-04-15       Impact factor: 31.743

Review 3.  Genetics and epigenetics of cutaneous malignant melanoma: a concert out of tune.

Authors:  Karin van den Hurk; Hanneke E C Niessen; Jürgen Veeck; Joost J van den Oord; Maurice A M van Steensel; Axel Zur Hausen; Manon van Engeland; Véronique J L Winnepenninckx
Journal:  Biochim Biophys Acta       Date:  2012-03-31

4.  A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations.

Authors:  Sreenath V Sharma; Diana Y Lee; Bihua Li; Margaret P Quinlan; Fumiyuki Takahashi; Shyamala Maheswaran; Ultan McDermott; Nancy Azizian; Lee Zou; Michael A Fischbach; Kwok-Kin Wong; Kathleyn Brandstetter; Ben Wittner; Sridhar Ramaswamy; Marie Classon; Jeff Settleman
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

5.  Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.

Authors:  Rizwan Haq; Jonathan Shoag; Pedro Andreu-Perez; Satoru Yokoyama; Hannah Edelman; Glenn C Rowe; Dennie T Frederick; Aeron D Hurley; Abhinav Nellore; Andrew L Kung; Jennifer A Wargo; Jun S Song; David E Fisher; Zolt Arany; Hans R Widlund
Journal:  Cancer Cell       Date:  2013-03-07       Impact factor: 31.743

6.  DNA-methylation profiling distinguishes malignant melanomas from benign nevi.

Authors:  Kathleen Conway; Sharon N Edmiston; Zakaria S Khondker; Pamela A Groben; Xin Zhou; Haitao Chu; Pei Fen Kuan; Honglin Hao; Craig Carson; Marianne Berwick; David W Olilla; Nancy E Thomas
Journal:  Pigment Cell Melanoma Res       Date:  2011-02-18       Impact factor: 4.693

7.  Cross-platform array screening identifies COL1A2, THBS1, TNFRSF10D and UCHL1 as genes frequently silenced by methylation in melanoma.

Authors:  Vanessa F Bonazzi; Derek J Nancarrow; Mitchell S Stark; Ralf J Moser; Glen M Boyle; Lauren G Aoude; Christopher Schmidt; Nicholas K Hayward
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

8.  A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma.

Authors:  Satoru Yokoyama; Susan L Woods; Glen M Boyle; Lauren G Aoude; Stuart MacGregor; Victoria Zismann; Michael Gartside; Anne E Cust; Rizwan Haq; Mark Harland; John C Taylor; David L Duffy; Kelly Holohan; Ken Dutton-Regester; Jane M Palmer; Vanessa Bonazzi; Mitchell S Stark; Judith Symmons; Matthew H Law; Christopher Schmidt; Cathy Lanagan; Linda O'Connor; Elizabeth A Holland; Helen Schmid; Judith A Maskiell; Jodie Jetann; Megan Ferguson; Mark A Jenkins; Richard F Kefford; Graham G Giles; Bruce K Armstrong; Joanne F Aitken; John L Hopper; David C Whiteman; Paul D Pharoah; Douglas F Easton; Alison M Dunning; Julia A Newton-Bishop; Grant W Montgomery; Nicholas G Martin; Graham J Mann; D Timothy Bishop; Hensin Tsao; Jeffrey M Trent; David E Fisher; Nicholas K Hayward; Kevin M Brown
Journal:  Nature       Date:  2011-11-13       Impact factor: 49.962

9.  A DNA hypermethylation module for the stem/progenitor cell signature of cancer.

Authors:  Hariharan Easwaran; Sarah E Johnstone; Leander Van Neste; Joyce Ohm; Tim Mosbruger; Qiuju Wang; Martin J Aryee; Patrick Joyce; Nita Ahuja; Dan Weisenberger; Eric Collisson; Jingchun Zhu; Srinivasan Yegnasubramanian; William Matsui; Stephen B Baylin
Journal:  Genome Res       Date:  2012-03-05       Impact factor: 9.043

10.  Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients.

Authors:  Luca Sigalotti; Alessia Covre; Elisabetta Fratta; Giulia Parisi; Paolo Sonego; Francesca Colizzi; Sandra Coral; Samuele Massarut; John M Kirkwood; Michele Maio
Journal:  J Transl Med       Date:  2012-09-05       Impact factor: 5.531

View more
  25 in total

Review 1.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

2.  A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF.

Authors:  Jiyeon Choi; Mai Xu; Matthew M Makowski; Tongwu Zhang; Matthew H Law; Michael A Kovacs; Anton Granzhan; Wendy J Kim; Hemang Parikh; Michael Gartside; Jeffrey M Trent; Marie-Paule Teulade-Fichou; Mark M Iles; Julia A Newton-Bishop; D Timothy Bishop; Stuart MacGregor; Nicholas K Hayward; Michiel Vermeulen; Kevin M Brown
Journal:  Nat Genet       Date:  2017-07-31       Impact factor: 38.330

3.  The DNA methylation landscape of human melanoma.

Authors:  Seung-Gi Jin; Wenying Xiong; Xiwei Wu; Lu Yang; Gerd P Pfeifer
Journal:  Genomics       Date:  2015-09-15       Impact factor: 5.736

Review 4.  Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Med Sci (Basel)       Date:  2017-11-20

Review 5.  The Wnts of change: How Wnts regulate phenotype switching in melanoma.

Authors:  Marie R Webster; Curtis H Kugel; Ashani T Weeraratna
Journal:  Biochim Biophys Acta       Date:  2015-11-04

Review 6.  Phenotype plasticity as enabler of melanoma progression and therapy resistance.

Authors:  Imanol Arozarena; Claudia Wellbrock
Journal:  Nat Rev Cancer       Date:  2019-06-17       Impact factor: 60.716

Review 7.  Epigenetic mechanisms involved in melanoma pathogenesis and chemoresistance.

Authors:  Anna Martinez-Cardús; Miguel Vizoso; Sebastian Moran; Jose Luis Manzano
Journal:  Ann Transl Med       Date:  2015-09

8.  Integrative Analysis of Genome-Wide Association Studies and DNA Methylation Profile Identified Genetic Control Genes of DNA Methylation for Kashin-Beck Disease.

Authors:  Ping Li; Cuiyan Wu; Xiong Guo; Yan Wen; Li Liu; Xiao Liang; Yanan Du; Lu Zhang; Mei Ma; Shiqiang Cheng; Bolun Cheng; Sen Wang; Feng Zhang
Journal:  Cartilage       Date:  2019-06-20       Impact factor: 3.117

9.  Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress.

Authors:  Jennifer Tsoi; Lidia Robert; Kim Paraiso; Carlos Galvan; Katherine M Sheu; Johnson Lay; Deborah J L Wong; Mohammad Atefi; Roksana Shirazi; Xiaoyan Wang; Daniel Braas; Catherine S Grasso; Nicolaos Palaskas; Antoni Ribas; Thomas G Graeber
Journal:  Cancer Cell       Date:  2018-04-12       Impact factor: 38.585

Review 10.  How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance.

Authors:  Anja Wessely; Theresa Steeb; Carola Berking; Markus Vincent Heppt
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.